Biocon Limited has announced that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay) Injection, a biosimilar to Perjeta®. This approval marks Biocon’s fifth oncology biosimilar in the U.S. market and strengthens its oncology portfolio. Pebrilzo™ is indicated for the treatment of HER2-positive breast cancer. The company has secured a global settlement and license agreement for its earliest licensed launch date in the U.S. in Q3 2028.
Biocon Secures FDA Approval for Oncology Biosimilar
Biocon Limited today announced a significant milestone with the U.S. Food and Drug Administration’s (FDA) approval of Pebrilzo™ (pertuzumab-qcay) Injection. This marks Biocon’s fifth oncology biosimilar to receive FDA approval and represents a crucial expansion of its oncology portfolio in the United States.
Pebrilzo™: A New Treatment Option for Breast Cancer
Pebrilzo™, a biosimilar to the reference product Perjeta® (pertuzumab), is a monoclonal antibody used in the treatment of HER2-positive breast cancer. The FDA approval is seen as an important step towards broadening treatment options for patients, subject to an anticipated commercial launch timeline. The drug functions by blocking HER2 receptors on cancer cells, thereby inhibiting aggressive tumor growth.
Global Settlement and Launch Timeline
Biocon has also entered into a global settlement and license agreement with Genentech. This agreement secures the earliest licensed launch date for Pebrilzo™ in the United States for the third quarter of calendar year 2028.
Strengthening Biocon’s Oncology Portfolio
The addition of Pebrilzo™ to Biocon’s offerings further solidifies its position in the oncology market. The company’s existing oncology portfolio includes biosimilar therapies such as Ogivri®, Jobevne®, Fulphila®, and Aukelso®. Biocon’s pipeline also includes proposed biosimilars for trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.
Indications and Safety Information
Pebrilzo™ is indicated for the treatment of Metastatic Breast Cancer (MBC) in combination with trastuzumab and docetaxel for patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated for Early Breast Cancer (EBC) in combination with trastuzumab and chemotherapy for neoadjuvant treatment of locally advanced, inflammatory, or early-stage breast cancer, and for adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence.
The drug carries warnings regarding Left Ventricular Dysfunction and Embryo-Fetal Toxicity. Patients are advised to undergo cardiac function evaluation before and during treatment. Contraindications include known hypersensitivity to pertuzumab or its excipients. Common adverse reactions listed include diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy, depending on the treatment regimen.
Source: BSE